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This study involving the recombinant acid lipase MERISPASE® [1,2] was con-
ducted in 24 CF adult patients during the six last months of 2007. The aim was
to conﬁrm the safety and the efﬁcacy of the r-lipase added with low doses of
CREON®.
This was a monocenter, single blind study according to cross-over and parallel
group protocols. Three sessions were designed: Session 1: all patients received low
doses of pancreatic extract; Session 2: patients treated with 3 different doses of
lipase compared with a fourth group taking 84,000 U of P E; Session 3: was the
add-on phase since all patients received low doses CREON® whereas the three
MERISPASE® group pursued. The full results will be given orally, but:
1. The safety was excellent with no severe side effects.
2. The tolerance was also good and all 24 adults completed the study.
3. MERISPASE® alone had as previously observed a dramatic effect on CFA when
this criteria was low at the beginning of the study.
4. However, MERISPASE® alone was unable to fully correct CFA. Its addition to
low doses of CREON® gave in contrast a similar result (without any differences
in the clinical signs of local tolerance) than when the patient was taking high
doses of pancreatic extract.
The results permitted us to design the phase III.
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